Richard Rosenquist Brandell

Richard Rosenquist Brandell

Professor/Överläkare
Besöksadress: Karolinska Institutet, BioClinicum J10:20, Visionsgatan 4, 17164 Solna
Postadress: K1 Molekylär medicin och kirurgi, K1 MMK Klinisk genetik, 171 76 Stockholm

Om mig

  • För mer information se den engelska sidan.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • The molecular landscape of chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2018
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively kind disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example, the time for treatment to be inserted or total survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to determine in advance whether a particular subgroup of patients benefit from a particular treatment, something that is not possible at present.
  • The molecular landscape of chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2017
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively kind disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example, the time for treatment to be inserted or total survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to determine in advance whether a particular subgroup of patients benefit from a particular treatment, something that is not possible at present.
  • The molecular landscape of chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2016
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively kind disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example, the time for treatment to be inserted or total survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to determine in advance whether a particular subgroup of patients benefit from a particular treatment, something that is not possible at present.
  • Characterization of the molecular landscape in chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2015
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively "kind" disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example the time for treatment to be inserted or survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to predetermine whether a particular subgroup of patients benefit from a certain treatment, something that is not possible at present.
  • Characterization of the molecular landscape in chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2014
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively "kind" disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example the time for treatment to be inserted or survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to predetermine whether a particular subgroup of patients benefit from a certain treatment, something that is not possible at present.

Nyheter från KI

Kalenderhändelser från KI

Nyheter från externa medier